Paediatric rheumatology expert group meeting

• Date:
  Wednesday, 17 November 2010, All day
• Location:
  European Medicines Agency, Amsterdam, the Netherlands

Experts in the field of paediatric rheumatology from Europe and the United States of America are attending this meeting together with representatives of regulators from both sides of Atlantic. All aspects of development of medicines for children with juvenile idiopathic arthritis are being discussed, from non-clinical studies to pharmacovigilance measures. The conclusions of this meeting will create a basis for standardisation of paediatric investigation plans for chronic idiopathic arthritis, which has been found necessary by all stakeholders.

Documents

Agenda – Paediatric Rheumatology Expert Group Meeting

Reference Number: EMA/719882/2010

Conclusions from the Paediatric Rheumatology Expert Group Meeting

Reference Number: EMA/836276/2010

Presentation - Overview of the Paediatric Rheumatology Expert Meeting

Presentation - EU- RMP and Paediatric pharmacovigilance

Presentation - PHARMACHILD: A European collaboration on long term outcome and pharmacovigilance for biologics used in Juvenile Idiopathic Arthritis

Presentation - A randomized, double-blind trial of anti-TNF chimeric monoclonal antibody (Infliximab) in combination with methotrexate for the treatment of patients with polyarticular juvenile rheumatoid arthritis